Literature DB >> 18477279

Presumed interaction of fusidic acid with simvastatin.

A J Burtenshaw1, G Sellors, R Downing.   

Abstract

A 63-year-old man was admitted 6 weeks after an elective abdominal aortic aneurysm repair following which methicillin resistant Staphylococcus aureus (MRSA) had been cultured from the aneurysmal sac. He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis. Severe rhabdomyolysis was confirmed and despite prolonged and complicated critical care management, his treatment was unsuccessful. Extensive investigations ruled out other known causes of this clinical presentation and failed to identify any other precipitating cause of rhabdomyolysis. We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage. Increasing MRSA colonisation and infection rates together with increased statin usage have the potential to increase the incidence of this presumed drug interaction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18477279     DOI: 10.1111/j.1365-2044.2007.05434.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  7 in total

1.  Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid.

Authors:  Roselle Herring; Gordon Caldwell; Stuart Wade
Journal:  BMJ Case Rep       Date:  2009-09-20

2.  Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis.

Authors:  Santiago Vilar; Rave Harpaz; Herbert S Chase; Stefano Costanzi; Raul Rabadan; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2011-09-21       Impact factor: 4.497

3.  Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.

Authors:  Anshul Gupta; Jennifer J Harris; Jianrong Lin; James P Bulgarelli; Bruce K Birmingham; Scott W Grimm
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 4.  Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions.

Authors:  Thomas Deljehier; Antoine Pariente; Ghada Miremont-Salamé; Françoise Haramburu; Linh Nguyen; Sébastien Rubin; Claire Rigothier; Hélène Théophile
Journal:  Br J Clin Pharmacol       Date:  2018-02-26       Impact factor: 4.335

5.  Acute rhabdomyolysis associated with coadministration of levofloxacin and simvastatin in a patient with normal renal function.

Authors:  Maria Paparoupa; Sebastian Pietrzak; Adrian Gillissen
Journal:  Case Rep Med       Date:  2014-07-22

6.  Severe Rhabdomyolysis as Complication of Interaction between Atorvastatin and Fusidic Acid in a Patient in Lifelong Antibiotic Prophylaxis: A Dangerous Combination.

Authors:  Anirban Nandy; Shahin Gaïni
Journal:  Case Rep Med       Date:  2016-12-27

7.  Rhabdomyolysis Induced by Coadministration of Fusidic Acid and Atorvastatin: A Case Report and Comprehensive Review of the Literature.

Authors:  Dimitrios Patoulias; Theodoros Michailidis; Thomas Papatolios; Rafael Papadopoulos; Petros Keryttopoulos
Journal:  Case Rep Nephrol       Date:  2017-10-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.